Expand SGMT Menu
SGMT MENU

SGMT Stock Summary and Trading Ideas (Sagimet Biosciences - Series A | NASDAQ:SGMT)

Charts for Today's Stock Price and Implied Volatility in Sagimet Biosciences - Series A

20-Mar-2026

Stock Price & Volume | Full Chart

30-Day Implied Volatility | IV30 Full Chart

Trade Ideas for Best Option Strategies for SGMT by Theoretical Edge and Win Rates

Sentiment

News

Trading Statistics

Key Ratios

Sagimet Biosciences - Series A (SGMT) Frequently Asked Questions

What does Sagimet Biosciences - Series A do?

Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.

What symbol and exchange does Sagimet Biosciences - Series A shares trade?

Sagimet Biosciences - Series A trades on the NASDAQ stock market under the symbol SGMT.

What is Sagimet Biosciences - Series A stock price doing today?

As of March 20, 2026, SGMT stock price declined to $4.82 with 358,439 million shares trading.

What is Sagimet Biosciences - Series A's Beta?

SGMT has a beta of 3.61, meaning it tends to be more sensitive to market movements. SGMT has a correlation of 0.30 to the broad based SPY ETF.

How much is Sagimet Biosciences - Series A worth?

SGMT has a market cap of $157.06 million. This is considered a Micro Cap stock.

How much money does Sagimet Biosciences - Series A make?

Last quarter Sagimet Biosciences - Series A reported $0 in Revenue and -$.29 earnings per share. This fell short of revenue expectation by $-1 million and exceeded earnings estimates by $.12.

What are the top ETFs holding Sagimet Biosciences - Series A?

The top ETF exchange traded funds that SGMT belongs to (by Net Assets): VTI, VXF, IBB, IWC, DFAS.

Is Sagimet Biosciences - Series A (SGMT) a good investment?

SGMT has outperformed the market in the last year with a return of +19.0%, while the SPY ETF gained +16.6%. However, in the most recent history, SGMT shares have underperformed the stock market with its stock returning -23.2% in the last 3 month period and -10.9% for the last 2 week period, while SPY has returned -4.4% and -3.3%, respectively.

What are the support and resistance levels for Sagimet Biosciences - Series A (SGMT)?

SGMT support price is $4.61 and resistance is $5.05 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SGMT shares will trade within this expected range on the day.

Market Data Delayed 15 Minutes